


## Viral Epidemiology Snapshot: November 10-16, 2024


Prepared by Anne Hall, Ph.D., M(ASCP) on behalf of the Molecular Diagnostics/Virology Labs

CoV-2, Flu, & RSV					
<u>Virus</u>	#Tested	#Positive	% Positive		
Flu A	488	9	1.8%		
Flu B	488	1	0.2%		
RSV	372	15	4.0%		
CoV-2	470	19	4.0%		

Bacterial Respiratory Infections (Molecular Tests)					
<u>Organism</u>	#Tested	#Positive	% Positive		
Bordetella parapertussis	353	0	0.0%		
Bordetella pertussis	353	2	0.6%		
Chlamydia pneumoniae	344	0	0.0%		
Mycoplasma pneumoniae	347	23	6.6%		

Other Respiratory Viruses					
<u>Virus</u>	#Tested	#Positive	% Positive		
Adenovirus	344	17	4.9%		
Coronavirus 229E	344	0	0.0%		
Coronavirus HKU1	344	0	0.0%		
Coronavirus NL63	344	2	0.6%		
Coronavirus OC43	344	0	0.0%		
Metapneumovirus	344	4	1.2%		
Rhinovirus/Enterovirus	344	128	37.2%		
Parainfluenza 1	344	19	5.5%		
Parainfluenza 2	344	0	0.0%		
Parainfluenza 3	344	2	0.6%		
Parainfluenza 4	344	24	7.0%		





Flu A Subtyping		
2009 H1N1	0	
Seasonal H1	0	
Seasonal H3	1	
No Subtype	8	
Pending subtype	0	

This report contains results for all tests ordered throughout the CHMCA network. As of 9/19/23, the data set includes all Point of Care Testing performed at ACHPs and Urgent Care Centers, as well as the central hospital laboratories.

As of 10/1/23, SARS-CoV-2 will be tracked in total, rather than in "Diagnostic" and "Screening" categories

The top chart displays the 8-week trend for total number of positive tests for Flu A, Flu B, RSV, and SARS-CoV-2.

The bottom chart displays the 8-week trend for positivity rate (# positive/ total # tested) Flu A, Flu B, RSV, and SARS-CoV-2.

